This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on Web of Science (2)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in JAMA  Social Bookmarking   What's this?

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

To the Editor.—Procter & Gamble's movie theater study¹ does a good job of answering the wrong questions. It fails to demonstrate a significantly increased incidence of gastrointestinal (GI) effects from a one-time, variable olestra exposure. But it sheds little light on what will happen when large numbers of Americans consume olestra over prolonged periods. Also, JAMA's "Editor's Note" was incorrect in stating that "controlled studies [on olestra's GI effects] have not been reported."²

In fact, several well-designed clinical trials reported to the Food and Drug Administration as part of the olestra approval process and published in the Federal Register³ show significant increases in GI symptoms during 5 to 56 days of daily olestra consumption. In 2 trials sponsored by Procter & Gamble, groups of 17 to 24 subjects fed 20 or 32 g of olestra (equivalent to about 56 g [2 oz] or 98 g [3.5 oz] of potato . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLE

Gastrointestinal Symptoms Following Consumption of Olestra or Regular Triglyceride Potato Chips: A Controlled Comparison
Lawrence J. Cheskin, Robert Miday, Nora Zorich, and Thomas Filloon
JAMA. 1998;279(2):150-152.
ABSTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Authors' Financial Relationships With the Food and Beverage Industry and Their Published Positions on the Fat Substitute Olestra
Levine et al.
AJPH 2003;93:664-669.
ABSTRACT | FULL TEXT